Background Patients with chronic kidney disease (CKD) and stable ischemic heart disease are at markedly increased risk of cardiovascular events. Prior trials comparing a strategy of optimal medical therapy (OMT) with or without revascularization have largely excluded patients with advanced CKD. Whether a routine invasive approach when compared with a conservative strategy is beneficial in such patients is unknown.
Methods ISCHEMIA-CKD is a National Heart, Lung, and Blood Institute-funded randomized trial designed to determine the comparative effectiveness of an initial invasive strategy (cardiac catheterization and optimal revascularization [percutaneous coronary intervention or coronary artery bypass graft surgery, if suitable] plus OMT) versus a conservative strategy (OMT alone, with cardiac catheterization and revascularization [percutaneous coronary intervention or coronary artery bypass graft surgery, if suitable] reserved for failure of OMT) on long-term clinical outcomes in 777 patients with advanced CKD (defined as those with estimated glomerular filtration rate b30 mL/min/1.73m 2 or on dialysis) and moderate or severe ischemia on stress testing. Participants were randomized in a 1:1 fashion to the invasive or a conservative strategy. The primary end point is a composite of death or nonfatal myocardial infarction.
Major secondary endpoints are a composite of death, nonfatal myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, or resuscitated cardiac arrest; angina control; and disease-specific quality of life. Safety outcomes such as initiation of maintenance dialysis and a composite of initiation of maintenance dialysis or death will be reported. The trial is projected to have 80% power to detect a 22% to 24% reduction in the primary composite end point with the invasive strategy when compared with the conservative strategy.
Conclusions ISCHEMIA-CKD will determine whether an initial invasive management strategy improves clinical outcomes when added to OMT in patients with advanced CKD and stable ischemic heart disease. (Am Heart J 2018;205: 42-52.) Cardiovascular disease is the leading cause of death among patients with chronic kidney disease (CKD), 1,2 with a rate 15-30 times higher than age-adjusted cardiovascular mortality in the general population. 3, 4 Patients with CKD are more likely to die from cardiovascular causes than to experience progression to end-stage renal disease requiring dialysis or transplantation. 5, 6 Despite the strong link between CKD and cardiovascular disease,~80% of contemporary stable ischemic heart disease (SIHD) trials have excluded patients with CKD, presumably because of this high antecedent risk. 7, 8 Most treatments aimed at reducing cardiovascular events in patients with CKD are extrapolated from prior trials enrolling largely patients without CKD. Patients with CKD were also underrepresented in contemporary SIHD trials comparing coronary revascularization with medical therapy, including the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial, 9 the Clinical Outcomes Utilizing
Revascularization and Aggressive Drug Evaluation (COUR-AGE) trial, 10 and the Fractional Flow Reserve versus Angiography for Multivessel Evaluation 2 trial. 11 The above trials failed to show that an initial invasive strategy reduced the risk of death or myocardial infarction (MI) when compared with an initial conservative strategy of medical therapy alone.
Patients with CKD are at increased risk for procedural complications from coronary revascularization, including acute kidney injury (AKI), major bleeding, vessel dissection, MI, and death. [12] [13] [14] Observational studies in CKD suggest lower long-term mortality rates in patients with SIHD who were revascularized when compared with patients who did not undergo revascularization, 15 despite an increase in short-term risks. However, these "benefits" may be due to selection biases, compounded by the fact that the medical therapy in these studies was variable and not optimized. For this reason, there is an unmet need to better understand the optimal management of patients with SIHD and advanced CKD. [16] [17] [18] To address these uncertainties, we are conducting the ISCHEMIA-CKD (NCT01985360) trial, an international, randomized comparative effectiveness trial that is designed to test the incremental value of an initial invasive strategy when added to optimal medical therapy (OMT) in patients with SIHD and advanced CKD.
Methods
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Study design and population
The primary aim of ISCHEMIA-CKD is to determine whether an initial invasive strategy of cardiac catheterization and revascularization (percutaneous coronary intervention [PCI] or coronary artery bypass graft surgery [CABG] ), if suitable, in addition to OMT, will reduce the primary end point of all-cause death or nonfatal MI in 777 participants with moderate or severe ischemia and advanced CKD (defined as patients with estimated glomerular filtration rate [eGFR] b30 mL/min/1.73 m 2 or on dialysis) compared with a conservative strategy of OMT alone, with cardiac catheterization and revascularization (PCI or CABG, if suitable) reserved for failure of OMT (Figure 1 ). The secondary aims are to compare other clinical and economic outcomes as prespecified in the protocol and/or the Statistical Analysis Plan. Safety outcomes such as initiation of maintenance dialysis and a composite of initiation of maintenance dialysis or death will be reported. ISCHEMIA-CKD was designed to run in parallel with the ISCHEMIA Trial (NCT01471522), which randomized patients with eGFR ≥30 mL/min/ 1.73 m 2 and moderate or severe ischemia in 1:1 fashion to invasive or conservative strategies.
Patients with advanced CKD and moderate or severe ischemia on stress testing were screened for study inclusion, the details of which are shown in Table I . The first patient was randomized on May 12, 2014 , and the last patient on January 31, 2018 (Figure 2) .
Patients who met the clinical and ischemia (site-interpreted) eligibility criteria (Table II) and who gave written informed consent were randomized in a 1:1 fashion to an invasive or conservative strategies (Figure 1 ). Randomized allocation of treatment strategy was performed via a central interactive voice response system and interactive Web response system. Treatment allocation was open label. Participants were randomized over approximately 3.7 years, with follow-up projected for an average of approximately 2.8 years. The minimum follow-up period will be approximately 18 months following randomization of the final subject. The study is being performed in accordance with ethical principles of the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. The final study protocol and informed consent were reviewed and approved by the corresponding health authorities and ethics boards/institutional review boards of all participating study sites. The trial was funded by the National Heart, Lung, and Blood Institute (NHLBI).
Management strategies and study assessments
Conservative strategy. In participants randomized to the conservative strategy, management is focused on the provision of OMT. A fundamental principle of the conservative strategy is to restrict cardiac catheterization (and revascularization if suitable) only to participants who fail OMT, that is, those who experience an acute coronary syndrome, acute ischemic heart failure, or resuscitated cardiac arrest or who have angina refractory to medical therapy ( Figure 3) . If angina worsens, medical therapy is intensified first (eFigure 1). If symptoms are refractory to maximally tolerated medical therapy or become unstable, participants undergo cardiac catheterization. In such participants, revascularization (PCI or CABG) is performed using the principles of optimal revascularization as described below. Optimal medical therapy. Optimal medical therapy consists of intensive, comprehensive secondary prevention with lifestyle and pharmacologic intervention applied equally to both treatment groups using individualized treatment regimens based on treat-to-target algorithms. The site study team works in collaboration with the participant's principal care physician (internal medicine physician, nephrologist, or cardiologist) to achieve OMT goals. Study coordinators have been trained to provide lifestyle counseling focused on smoking cessation, nutrition, physical activity, and medication adherence. Pharmacologic interventions include antiatherothrombotic and anti-ischemic medications. Treatment algorithms were developed and recommended for management of low-density lipoprotein cholesterol (LDL-C), blood pressure, and angina (eFigure 1). The minimum goals of OMT are those recommended by the American College of Cardiology, American Heart Association, and the European Society of Cardiology for secondary prevention and angina management; the National Kidney Foundation; and the UK Renal Association. [19] [20] [21] [22] [23] [24] [25] There are challenges to the implementation of OMT, as the evidence upon which the guidelines are based for patients with advanced CKD, and especially those on dialysis, is limited (most randomized trials excluded these high-risk patients). However, cardiovascular disease guideline recommendations are the existing standards and are used in ISCHEMIA-CKD with some modification, as outlined in Table III . In addition, diagnosis, evaluation, prevention, and treatment of CKD-related conditions, including anemia and mineral and bone disorders, are based on local practice and in accordance with national and international guidelines for kidney disease. Moreover, the choice of dialysis modality, the access site for dialysis, duration of dialysis, and other strategies for adequate dialysis (such as dialysate temperature) are based on local practice. Dose adjustments are recommended for medications that are renally excreted or dialyzed.
In patients on dialysis, there is no clear consensus as to which (predialysis, postdialysis, or interdialytic) blood pressure should be used as the guide for therapy. Based on the 2017 American College of Cardiology/American Heart Association blood pressure guidelines 26 (although specific recommendations for subjects on dialysis are lacking), we recommend an office blood pressure goal of b130/80 mm Hg for all participants in the ISCHEMIA-CKD trial. Significantly lower blood pressure (eg, b110 mm Hg systolic) should be avoided. Controversy persists about the safety and efficacy of statins in patients with advanced CKD. Two large randomized controlled trials of statins in patients receiving hemodialysis (Die Deutsche Diabetes Dialyse Studie and the Assessment of Survival and Cardiovascular Events trial) failed to show benefits. 27, 28 However, in the Study of Heart and Renal Protection, 29 simvastatin with ezetimibe resulted in a significant 17% (95% CI 6%-26%) reduction in the risk of major adverse cardiac events when compared with placebo in patients with advanced CKD on or not on dialysis. Although the effect of simvastatin + ezetimibe was significant in the nondialysis CKD stratum and not significant in the dialysis stratum, there was no significant interaction observed between the 2 strata, prompting clinical practice guidelines to recommend lipid-lowering therapy in advanced CKD, specifically for the prevention of atherosclerotic events. 23, 24 However, neither Study of Heart and Renal Protection nor the Die Deutsche Diabetes Dialyse Studie or Assessment of Survival and Cardiovascular Events trials enrolled a patient population similar to the ISCHEMIA-CKD population. Thus, for participants with advanced, non-dialysis-requiring CKD in ISCHEMIA-CKD, high-intensity statin therapy is recommended. If high-intensity statin therapy cannot be tolerated, moderate-intensity statin therapy is recommended. For subjects on dialysis, moderate-or high-intensity statin treatment is recommended as tolerated. Optimizing medical therapy goal attainment. To improve medication adherence, the trial is able to provide certain medications at no cost to participants in some countries. Monthly reports on attainment of risk factor goals are provided to sites by the Clinical Coordinating Center. Sites where the attainment of OMT goals is below average are reeducated, and site-specific corrective action plans are developed in conjunction with the study team. In addition, medication adherence is tracked using the Morisky-Green-Levine medication adherence survey. 30 Management of angina. Medical management of angina in the conservative strategy is intensified according to the ISCHEMIA-CKD angina treatment algorithm (eFigure 1). The goal for participants randomized to the conservative strategy arm is to control angina such that participants report a satisfactory angina-related quality of life. If the level of angina is unacceptable to the participant despite maximally tolerated medical therapy, cardiac catheterization and revascularization (PCI or CABG if suitable) are recommended, consistent with standard of care.
Participants randomized to the invasive strategy who experience angina following revascularization may be treated medically, as per the ISCHEMIA-CKD angina treatment algorithm (eFigure 1). The goal for participants randomized to the invasive strategy is to control angina such that participants report a satisfactory angina-related quality of life. Unlike participants randomized to the conservative strategy, participants randomized to the invasive strategy could undergo repeat cardiac catheterization and revascularization (PCI or CABG if suitable) without first maximizing medical therapy.
Invasive strategy. Participants randomized to the invasive strategy underwent cardiac catheterization within 30 days of randomization, if feasible, with optimal revascularization (PCI or CABG) therapy based upon coronary anatomy and other clinical considerations soon Participant recruitment and active randomizing sites. Invasive procedures and protocol adherence. 1 Heart-kidney team recommended for left main disease, complex multivessel disease, or whenever in doubt. 2 FFR is recommended for stenosis b50% if PCI is considered and stress imaging shows ischemia in the corresponding territory; FFR is recommended for stenosis b80% if PCI is considered and stress imaging does not show ischemia in the corresponding territory. 3 Use of iFR instead of FFR (where available) was permitted using a cutoff of ≤0.89 for physiologic significance. 4 Includes suspected hospitalization for unstable angina, ischemic heart failure, resuscitated sudden cardiac arrest, or MI. Figure 3 ) to discuss complex cases after the diagnostic angiogram was performed to reach a consensus as to the best revascularization technique and approach. Optimizing PCI. Patients with advanced non-dialysisrequiring CKD are at increased risk of AKI following PCI. However, there is controversy in the medical literature regarding the incidence (b1% to N30%), effective treatment (saline hydration, N-acetyl cysteine, or sodium bicarbonate) and prognosis of AKI (b0.5% to N5% requiring dialysis). [31] [32] [33] [34] The strategies to reduce the risk of AKI in participants enrolled in the ISCHEMIA-CKD trial are outlined in eTable I. For participants randomized to the invasive strategy and not on dialysis, a customized hydration protocol based on the Prevention of Contrast Renal Injury with Different Hydration Strategies trial 35 and contrast volume threshold (for hard stop) was provided to the site based on the participant's eGFR and body weight, along with protocols for ultra-lowvolume 36 and zero-contrast PCI techniques. 37 In addition, other recommendations to optimize PCI in this high-risk group included emphasis on complete functional revascularization (based on results of noninvasive stress test, FFR/iFR, or angiography), use of newer-generation drugeluting stents (preferably the everolimus-eluting stents [Xience] and slow-release zotarolimus-eluting stents [Endeavor Resolute], which were provided free of charge for trial participants randomized to the invasive strategy), techniques to reduce the risk of bleeding (use of transradial angiography, renal dosing of antithrombotic medications), and liberal use of FFR/iFR for intermediate lesions (FFR wires from St Jude Medical and Phillips were provided free of charge for trial participants randomized to the invasive strategy). The use of bare metal stents, other drug-eluting stents, or bioresorbable scaffolds was discouraged. Optimizing CABG. Patients with advanced non-dialysisrequiring CKD are at increased risk of AKI following CABG. Strategies to reduce the risk of AKI in those undergoing CABG are outlined in eTable II. Other recommendations to optimize CABG included accurate assessment and evaluation of potential CABG participants; complete revascularization when feasible; optimal intraoperative management, including protection from myocardial, renal, and associated organ and system injury; maximizing opportunity for long-term graft patency by using multiple arterial grafts and especially a left internal mammary artery graft; and provision of optimal secondary prevention of atherosclerotic cardiovascular events following CABG. Visit schedule and follow-up. Randomized participants are followed up at 1.5, 3, 6, and 12 months following randomization during the first year and every 6 months thereafter until planned follow-up completion in June 2019 (eTable III for schedule of visits). During follow-up visits, participants are assessed for potential end point events, medication adherence (using the Morisky-GreenLevine medication adherence survey), lifestyle adherence (using Patient-Centered Assessment and Counseling for Exercise), and health-related quality of life (QoL) (using brief symptoms/QoL assessment described below). At every follow-up visit, the research team, in collaboration with the treating physician(s), evaluates the effectiveness of medical therapy and optimizes therapy as needed, according to guideline recommendations and study algorithms. All participants are followed regardless of whether they adhere to the randomized treatment strategy.
Study endpoints. The primary end point is a composite of death or nonfatal MI. The major secondary endpoints are a composite of death, nonfatal MI, hospitalization for unstable angina, hospitalization for heart failure, or resuscitated cardiac arrest, and angina control using the brief Seattle Angina Questionnaire (SAQ) Angina Frequency Scale and the QoL Scale. Safety outcomes such as initiation of maintenance dialysis and a composite of initiation of maintenance dialysis or death will be reported. Other endpoints are listed in Table IV and outlined in the study protocol and/or the Statistical Analysis Plan.
An independent clinical events adjudication committee reviews and adjudicates all site-reported primary end point events and selected secondary endpoints in a blinded fashion based on study definitions (eTable III). The following endpoints are adjudicated: death (including cause), MI, resuscitated cardiac arrest, hospitalization for unstable angina, hospitalization for heart failure, and stroke/transient ischemic attack. Because the trial is an open-strategy trial, bias in the ascertainment of events is mitigated in several ways. These include carefully constructed data collection instruments (such as use of triggers/queries and algorithms to capture potential missed events [eg, cardiac biomarker elevation; hospitalization for other reasons, including chest pain, dyspnea, or pneumonia; and New York Heart Association class IV or Canadian Cardiovascular Society class IV on study visits]), screening of core laboratory data, site investigator and coordinator awareness regarding standard clinical events adjudication committee processes and requests, and manual triggering of events found during review of source documents. Extensive cross variable checks, random and for-cause document reviews, and queries have been under way from trial inception to ensure complete ascertainment and site reporting of any potential end point event. Later in the trial, examination of site variation in anticipated versus observed event reporting was initiated, with additional monitoring for sites with low numbers of events. No concerns have been identified to date based on these efforts.
Statistical considerations. All major treatment comparisons between the randomized groups will be performed according to the principle of "intention-totreat," that is, participants will be analyzed (and endpoints attributed) according to the randomized strategy assignment, irrespective of treatments actually received. Statistical comparisons and confidence intervals will be performed using 2-sided significance tests.
The statistical comparison of the 2 randomized groups with respect to the primary composite end point will be a "time-to-event" analysis and will therefore be based on the time from randomization to the first occurrence of either death or nonfatal MI. To account for heterogeneity among trial participants, the overall comparison will be adjusted for a prespecified set of prognostically important baseline covariates including age, sex, kidney function (dialysis status; eGFR among participants not on dialysis), ejection fraction, and the presence of diabetes. The level of significance for the assessment of the primary end point will be α = .05. In addition to Cox regression analyses, event-free survival probabilities not assuming proportional hazards will be estimated as a function of follow-up time in each treatment group using the KaplanMeier method and presented with pointwise 95% CIs. If the data provide evidence of an overall difference in outcome between management strategy groups, we will further examine whether the therapeutic effect is similar for all categories of participants or whether it varies according to specific participant characteristics, as prespecified in the Statistical Analysis Plan.
ISCHEMIA-CKD was originally designed to randomize approximately 1,000 participants. The sample size was estimated to provide 80%-95% power to detect a 15% to 19% relative reduction in the primary composite end point assuming that the 4-year cumulative rate of the primary composite end point is 50%-70% in participants randomized to the conservative strategy. The projected event rate for the primary composite end point in the conservative strategy participants was based on multiple observational studies, although none enrolled precisely the cohort under consideration. Slower-than-expected recruitment led study leadership to request approval from NHLBI to reduce the target sample size to 500-700 participants. This change was justified on the basis of an updated literature review supporting a range of possible treatment effects consistent with adequate power under the reduced sample size. This request was approved by NHLBI in late 2015. In an attempt to mitigate the loss of statistical power, follow-up was extended by 6 months. The revised target was ultimately exceeded because of higher-than-expected recruitment in 2016-2017. The final sample size of 777 participants is estimated to provide 80% power to detect a 22% to 24% relative reduction in the 4-year rate of the primary end point under assumptions consistent with the accumulating trial data.
Participants enrolled in the ISCHEMIA-CKD trial are a high-risk cohort. There is precedent from prior cardiovascular trials in high-risk cohorts to assume a relatively large treatment effect size. Prior NHLBI-funded trials such as the Surgical Treatment for Ischemic Heart Failure trial (heart failure with reduced ejection fraction) was powered for a 25% risk reduction, and the Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease trial 38 of patients with diabetes and multivessel coronary disease was powered for a 27% reduction in risk. Similarly, more recent trials in patients with ST-segment elevation MI such as the Complete Versus Lesion-Only Primary PCI Trial trial, 39 Preventive Angioplasty in Acute Myocardial Infarction, 40 and the DANAMI-3-PRIMULTI 41 42 observed a 57% reduction in risk of cardiac death, MI, or unstable angina with revascularization (PCI or CABG) when compared with medical therapy (aspirin and short-acting nifedipine); however, the trial was prematurely terminated after only 26 participants were enrolled. Similarly, in a meta-analysis of 38 nonrandomized studies of 85,731 patients with CKD, a 27% lower mortality was observed with coronary revascularization when compared with no revascularization. 15 Analysis of quality of life outcomes. Patients' QoL is assessed using the disease-specific brief SAQ 43 and the Rose Dyspnea Scale. The SAQ has been extensively validated in patients with SIHD. 44, 45 The primary analyses will be conducted using continuous health status scores, which will also be categorized to facilitate clinical interpretation (eg, any angina vs none). Given that participants, especially those assigned to the invasive strategy, are expected to experience a nonlinear improvement in QoL following randomization, with rapid gains during the first 6 months followed by continued gradual improvement through the end of follow-up, we will use piecewise linear growth curves with knots at 3 and 6 months to quantify changes through 3 months, between 3 and 6 months, and between 6 months and the end of follow-up. QoL analyses will therefore fit these curves using hierarchical linear (for continuous outcomes) or generalized linear (for dichotomous and ordinal outcomes) models and will include participant-specific random effects for the growth-curve parameters, corresponding fixed-effect parameters representing the trajectory for an "average" participant, fixed effects for treatment and treatment-by-trajectory interaction terms, and adjustment for baseline QoL as a covariate. The key outcome of interest to be compared between treatment groups is the average QoL over the duration of follow-up, calculated as the area under the mean model-estimated growth curve for each treatment group.
Data and Safety Monitoring Committee. A Data and Safety Monitoring Board (DSMB) was appointed by the NHLBI to monitor participant safety and to independently review performance of the trial. The ISCHEMIA-CKD DSMB membership includes all individuals on the ISCHEMIA trial DSMB which was expanded to include a nephrologist. The DSMB reviews interim analyses of primary and secondary endpoints, additional safety events, and other information as requested by the Board. Interim monitoring. Interim treatment group comparisons are planned for the primary end point at least 2 times during the study and will be monitored with the use of 2-sided symmetric O'Brien-Fleming type boundaries. 46, 47 An α-spending function will be used to control the overall type I error probability for the primary end point at 5%. Country coordination is performed by cardiology and nephrology country leaders (eTable VI). As in the ISCHEMIA trial, each enrolling site was encouraged to have a lead noninvasive cardiologist principal investigator (typically the corresponding principal investigator), a lead interventional cardiologist, and a lead cardiovascular surgeon. In addition, each site was encouraged to have a lead nephrologist participate in the management of CKD issues in the participants and network with nephrology groups to help patient recruitment and management. The list of participating sites and personnel is provided in the supplementary appendix (eTable VI).
Discussion
Patients with SIHD and advanced CKD are underrepresented in contemporary clinical trials comparing optimal coronary revascularization and medical therapy versus OMT alone, providing very limited data on management of these challenging patients. We considered including patients with advanced CKD in the ISCHEMIA trial, that is, having no eGFR exclusion criterion. The COURAGE trial was designed without a creatinine cutoff for trial entry, yet only 16 patients with advanced CKD were enrolled in COURAGE, emphasizing the need for a dedicated trial to focus attention on this high-risk cohort and for successful enrollment. In addition, individuals with advanced CKD might have a high early risk-benefit ratio from coronary revascularization. It is unknown if these short-term increased risks could be offset by long-term clinical benefits. We were fortunate to secure a separate award from NHLBI to focus efforts on this understudied, high-risk population.
ISCHEMIA-CKD and ISCHEMIA: similarities and differences
The ISCHEMIA-CKD trial was designed using the ISCHEMIA trial infrastructure. This resulted in cost efficiencies because we used the same platforms as the ISCHEMIA trial (Clinical Coordinating Center, Statistical and Data Coordinating Center, InForm and interactive voice response system, same sites and organization). For these reasons, the cost of conducting the CKD trial was substantially lower than for a true stand-alone trial. ISCHEMIA-CKD differs from ISCHEMIA in several ways: (1) The ISCHEMIA-CKD primary end point is a 2-component composite (death or MI) versus the 5-component ISCHEMIA primary end point (cardiovascular death, MI, hospitalization for unstable angina, hospitalization for heart failure, or resuscitated cardiac arrest). The prespecified change in the ISCHEMIA trial primary end point from a 2-component composite primary end point (cardiovascular death or MI) to a 5-component composite end point is described elsewhere. 48, 49 An updated power analysis using aggregate event rate data in January 2018 indicated that the ISCHEMIA-CKD trial will have sufficient power for a range of possible treatment effects for the 2-component composite, and the incremental gain in power with the 5-component composite was marginal. A decision was therefore made to continue with the 2-component primary composite for ISCHEMIA-CKD. 2) Ischemia eligibility was determined by sites without core laboratory confirmation of ischemia severity (there are no imaging core laboratories for ISCHEMIA-CKD trial due to cost considerations and at the request of the NHLBI). (3) There was no requirement of coronary computed tomography angiography (CCTA) prior to randomization to rule out left main coronary artery disease or the absence of obstructive disease due to higher risk of AKI in those with nondialysis advanced CKD. In subjects on dialysis, the use of CCTA was left to the discretion of the site but not mandated given that heavy calcification may preclude accurate assessment of coronary stenosis. Exclusion of potential left main disease was left to site investigators based on clinical judgment using the stress test and hemodynamic findings. (4) Randomized treatment strategies were optimized to reduce the risk of renal injury. (5) Although the majority of ISCHEMIA trial sites were invited for participation in ISCHEMIA-CKD, additional sites not participating in ISCHEMIA were chosen based on their potential to enroll patients with advanced CKD.
In summary, ISCHEMIA-CKD will provide much needed evidence as to whether an initial invasive management strategy improves long-term clinical outcomes when added to OMT in patients with SIHD, moderate or severe ischemia on stress testing, and advanced CKD.
